Phosphorylation of eukaryotic translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-adrenergic cardiac myocyte hypertrophy

Circ Res. 2004 Apr 16;94(7):926-35. doi: 10.1161/01.RES.0000124977.59827.80. Epub 2004 Mar 4.

Abstract

Glycogen synthase kinase 3beta (GSK-3beta) negatively regulates cardiac hypertrophy. A potential target mediating the antihypertrophic effect of GSK-3beta is eukaryotic translation initiation factor 2Bepsilon (eIF2Bepsilon). Overexpression of GSK-3beta increased the cellular kinase activity toward GST-eIF2Bepsilon in neonatal rat cardiac myocytes, whereas LiCl (10 mmol/L) or isoproterenol (ISO) (10 micromol/L), a treatment known to inhibit GSK-3beta, decreased it. Immunoblot analyses using anti-S535 phosphospecific eIF2Bepsilon antibody showed that S535 phosphorylation of endogenous eIF2Bepsilon was decreased by LiCl or ISO, suggesting that GSK-3beta is the predominant kinase regulating phosphorylation of eIF2Bepsilon-S535 in cardiac myocytes. Decreases in eIF2Bepsilon-S535 phosphorylation were also observed in a rat model of cardiac hypertrophy in vivo. Overexpression of wild-type eIF2Bepsilon alone moderately increased cell size (+31+/-11%; P<0.05 versus control), whereas treatment of eIF2Bepsilon-transduced myocytes with LiCl (+73+/-22% versus eIF2Bepsilon only; P<0.05) or ISO (+84+/-33% versus eIF2Bepsilon only; P<0.05) enhanced the effect of eIF2Bepsilon. Overexpression of eIF2Bepsilon-S535A, which is not phosphorylated by GSK-3beta, increased cell size (+107+/-35%) as strongly as ISO (+95+/-25%), and abolished antihypertrophic effects of GSK-3beta, indicating that S535 phosphorylation of eIF2Bepsilon critically mediates antihypertrophic effects of GSK-3beta. Furthermore, expression of eIF2Bepsilon-F259L, a dominant-negative mutant, inhibited ISO-induced hypertrophy, indicating that eIF2Bepsilon is required for beta-adrenergic hypertrophy. Interestingly, expression of eIF2Bepsilon-S535A partially increased cytoskeletal reorganization, whereas it did not increase expression of atrial natriuretic factor gene. These results suggest that GSK-3beta is the predominant kinase mediating phosphorylation of eIF2Bepsilon-S535 in cardiac myocytes, which in turn plays an important role in regulating cardiac hypertrophy primarily through protein synthesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenoviridae / genetics
  • Adrenergic beta-Agonists / pharmacology
  • Adrenergic beta-Antagonists / pharmacology
  • Animals
  • Animals, Newborn
  • Atrial Natriuretic Factor / biosynthesis
  • Atrial Natriuretic Factor / genetics
  • Cardiomegaly / enzymology
  • Cardiomegaly / etiology
  • Cardiomegaly / pathology
  • Cells, Cultured / drug effects
  • Cells, Cultured / enzymology
  • Eukaryotic Initiation Factor-2B / metabolism*
  • Gene Expression Regulation / physiology
  • Genetic Vectors / genetics
  • Glycogen Synthase Kinase 3 / genetics
  • Glycogen Synthase Kinase 3 / physiology*
  • Glycogen Synthase Kinase 3 beta
  • Heart Ventricles / cytology
  • Hypertrophy
  • Isoproterenol / pharmacology
  • Lithium Chloride / pharmacology
  • Male
  • Myocardial Infarction / complications
  • Myocytes, Cardiac / enzymology*
  • Myocytes, Cardiac / pathology
  • Myosin Heavy Chains / biosynthesis
  • Myosin Heavy Chains / genetics
  • Peptide Chain Initiation, Translational / physiology
  • Phosphoserine / metabolism
  • Propranolol / pharmacology
  • Protein Processing, Post-Translational*
  • Rats
  • Rats, Wistar
  • Recombinant Fusion Proteins / physiology
  • Transduction, Genetic
  • Ventricular Remodeling / physiology

Substances

  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Eukaryotic Initiation Factor-2B
  • Recombinant Fusion Proteins
  • Phosphoserine
  • Atrial Natriuretic Factor
  • Propranolol
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, rat
  • Glycogen Synthase Kinase 3
  • Myosin Heavy Chains
  • Lithium Chloride
  • Isoproterenol